RA
CMPX icon

Royce & Associates’s Compass Therapeutics CMPX Stock Holding History

Royce & Associates’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.93M Sell
1,336,780
-283,018
-17% -$836K 0.02% 564
2026
Q1 		$8.57M Buy
1,619,798
+1,333,810
+466% +$7.7M 0.08% 372
2025
Q4 		$1.54M Buy
+285,988
New +$1.32M 0.02% 628

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Royce & Associates's CMPX Position: Q2 2026 in Review

Royce & Associates reduced its Compass Therapeutics (CMPX) stake by 17% in Q2 2026, selling an estimated $836K and leaving 1,336,780 shares worth $2.93M. The position accounts for 0.02% of the portfolio, ranked #564.

Royce & Associates first reported a position in CMPX in Q4 2025 and has held it in 3 quarters since. The position peaked at $8.57M in Q1 2026. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Royce & Associates held 1,336,780 shares of Compass Therapeutics worth $2.93M as of Q2 2026.
  • Royce & Associates sold 283,018 Compass Therapeutics shares in Q2 2026, an estimated $836K.
  • Compass Therapeutics made up 0.02% of Royce & Associates's portfolio in Q2 2026, its #564 holding.
  • Royce & Associates first reported a position in Compass Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Royce & Associates's Compass Therapeutics position peaked at $8.57M in Q1 2026.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.